SCHEMBL30320587

SCHEMBL30320587

CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3nn(C4CCOC4)c4ncnc(N)c34)cc2F)on1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK7 Q8TDX7 13/20 0.58
KDR P35968 5/20 0.58
PIK3CD O00329 4/20 0.58
ABL1 P00519 4/20 0.58
EGFR P00533 4/20 0.58
HCK P08631 4/20 0.58
SRC P12931 4/20 0.58
PIK3CA P42336 4/20 0.58
PIK3CB P42338 4/20 0.58
MTOR P42345 4/20 0.58
PIK3CG P48736 4/20 0.58
EPHB4 P54760 4/20 0.58
PRKDC P78527 4/20 0.58
PI4KB Q9UBF8 4/20 0.58
LCK P06239 1/20 0.49
BRAF P15056 2/20 0.48
KRAS P01116 1/20 0.48
RAF1 P04049 1/20 0.48
MAP2K2 P36507 1/20 0.48
MAP2K1 Q02750 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24096695 1.00 NEK7 (0.58) NEK7KDRPIK3CDABL1EGFR
SCHEMBL24096512 0.96 NEK7 (0.57) NEK7KDRPIK3CDABL1EGFR
SCHEMBL30320665 0.96 NEK7 (0.57) NEK7KDRPIK3CDABL1EGFR
SCHEMBL30320675 0.94 NEK7 (0.60) NEK7KDRPIK3CDABL1EGFR
SCHEMBL24096465 0.94 NEK7 (0.60) NEK7KDRPIK3CDABL1EGFR
SCHEMBL24096464 0.93 NEK7 (0.65) NEK7KDRSRCLCK
SCHEMBL30320601 0.93 NEK7 (0.65) NEK7KDRSRCLCK
SCHEMBL24096541 0.92 NEK7 (0.61) NEK7KDRPIK3CDABL1EGFR
SCHEMBL30320649 0.92 NEK7 (0.61) NEK7KDRPIK3CDABL1EGFR
SCHEMBL24096536 0.91 NEK7 (0.56) NEK7KDRSRCLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed
CN-116075513-A Inhibitors of NEK7 kinase 哈利亚治疗公司 2023-05-05 CN disclosed
EP-4161933-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2023-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 NEK7 1/4885KDR 4072/4885PIK3CD 1435/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 NEK7 1/4885KDR 4751/4885PIK3CD 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.